HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Vernon Bernardino reiterated a Buy rating on Citius Pharma (NASDAQ:CTXR) and maintained a $6 price target.
May 30, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citius Pharma receives a reiterated Buy rating from HC Wainwright & Co. analyst Vernon Bernardino, with a maintained $6 price target.
The reiterated Buy rating and maintained $6 price target by HC Wainwright & Co. analyst Vernon Bernardino indicates a positive outlook for Citius Pharma's stock in the short term. This news is important for investors as it reaffirms the analyst's confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100